Introduction
The presence of an additional primary tumor in a lung cancer patient is not uncommon. Duchateau et al. [1] showed that 17.2% of patients with nonsmall cell lung cancer (NSCLC) had a history of another primary malignancy and 4% of NSCLC patients had two or more other primary malignant tumors in addition to NSCLC. The TNM staging and management of such NSCLC patients are usually not complicated if the metachronous primary cancer has been in remission for years. One study showed that recurrence-free probabilities of NSCLC at 3 and 5 years from the time-point of 5 years after NSCLC tumor resection were 92 and 87%, respectively [2] . The 5-year recurrence-free probabilities from the time-point of 5 years after complete NSCLC tumor resection were 65-89% depending on lymph node involvement and the presence of intratumoral vascular invasion [2] . Another study found that the 5-year recurrence-free probability from the time-point 5 years after primary tumor resection was 93% in stage IA NSCLC [3] . However, the staging and treatment of recently diagnosed NSCLC patients who have another recent metachronous primary cancer or another synchronous primary cancer are challenging because of the difficulty in distinguishing NSCLC metastases from recurrence or metastases of the other metachronous primary cancer or synchronous primary cancer. Therefore, treatment decision-making is difficult and standardized treatment for such patients has not been established.
One method of facilitating decision-making in this situation is to establish tumor aggressiveness using the maximum standardized uptake value (SUV maxWB ) and to assess metabolic tumor burden using whole-body metabolic tumor volume (MTV WB ) and total lesion glycolysis (TLG WB ) on 2-deoxy-2-[ PET/CT. To our knowledge, the relationship between these quantitative PET measurements and OS in NSCLC patients with other primary tumors has not been reported. The SUV maxWB , MTV WB , and TLG WB have been found to be associated strongly with overall survival (OS) in patients with NSCLC [3] [4] [5] [6] [7] . An important association has also been found between patient survival and metabolic tumor burden in other types of cancer such as small cell lung cancer, head and neck cancer, thyroid cancer, pancreatic cancer, breast cancer, esophageal carcinoma, and gynecological malignancies [8] [9] [10] [11] [12] [13] [14] . We hypothesize that MTV WB , TLG WB , and SUV maxWB are associated with OS in patients who have an NSCLC and other metachronous or synchronous primary cancers. This study was carried out to test this hypothesis.
Patients and methods
This study was approved by our institutional review board and the requirement to obtain informed consent was waived.
Inclusion and exclusion criteria
Identification of patients with pretreatment PET/CT was performed in two steps: (i) merging the list of all patients with histopathologically confirmed NSCLC who were diagnosed and/or treated in our hospital (identified by our Cancer Registry personnel on the basis of ICD 9 diagnosis codes) with the list of all 18 F-FDG PET/CT patients between February 2004 and December 2014, which gave us the list of all NSCLC patients who had an 18 F-FDG PET/CT study and were treated in our medical center; and (ii) all those NSCLC patients who fulfilled the following inclusion criteria were initially selected from the merged list: (a) had undergone a baseline whole-body 18 F-FDG PET/CT scan before initial treatment of NSCLC in our medical center, (b) no known brain metastasis (our standard 18 F-FDG PET/CT scan does not cover the entire brain), and (c) with a diagnosis of another type of metachronous or synchronous primary cancer besides NSCLC. On the basis of the SEER definition [15] , we defined the other primary cancer as 'synchronous' if it was diagnosed within 2 months either before or after the 18 F-FDG PET/CT scan was performed for the evaluation of current NSCLC; otherwise, the other cancers were classified as 'metachronous'. NSCLC patients presenting with metachronous primary cancer(s) more than 2 months after the 18 F-FDG PET scan for the diagnosis or staging of NSCLC were excluded from this study as the other primary cancer(s) was unknown at the time of management of the NSCLC. NSCLC patients with a history of metachronous primary cancer(s) diagnosed more than 5 years before the 18 F-FDG PET scan for the diagnosis or staging of NSCLC were also excluded as their current NSCLC staging and their management were not expected to be complicated by their history of metachronous primary cancer(s) because most cancer recurrence occurs within the first 5 years after treatment [2] . Patients with a previous history of basal cell carcinoma of the skin were also excluded from the study as such tumors rarely metastasize [16] .
Clinical and survival data
Clinical data relevant to OS were collected by our Cancer Registry and confirmed by the authors (X.Z., F.L., T.W., Y.P.), including the patient's age, sex, date of the baseline 18 F-FDG PET/CT, NSCLC and histopathology, cancer therapy, and date of diagnosis of the other metachronous or synchronous primary cancer(s). The clinical TNM stage was assigned to each patient according to the seventh edition of the AJCC TNM staging system for lung cancer on the basis of 18 F-FDG PET/CT and diagnostic computed tomography (CT) [17] . The NSCLC treatment plans for all patients were determined by the patient's care oncologist(s) at the time of initial management. The NSCLC treatment types used for the analyses in this study included 'surgery' with curative intent (surgery alone or in combination with chemotherapy, radiation therapy, or chemotherapy plus radiation therapy), 'other treatments' (chemotherapy, radiation therapy, and chemotherapy plus radiation therapy), and no cancer treatment.
OS was the primary end point of the study and was defined as the interval from the date of the baseline 18 F-FDG PET/CT to the date the patient died of any cause or the date of last contact. Patients who were last known to be alive were censored at the date of last contact.
F-FDG PET/CT data acquisition and analysis
All the patients underwent a whole-body 18 F-FDG PET/CT scan from mid-thigh to mid-head in accordance with the National Cancer Institute guidelines [18] . In our medical center, all patients fasted for at least 4 h before intravenous administration of 370-555 MBq of 18 F-FDG. A whole-body static PET scan was acquired starting at the thighs and proceeding to the skull base 90 30 min following an injection of the 18 F-FDG. The plasma glucose levels of all patients were less than 200 mg/dl before 18 F-FDG administration. An early group of 70 (63.6%) patients from February 2004 to February 2012 underwent 18 F-FDG PET/CT scans performed with a scanner equipped with high-resolution bismuth germanate detectors and a dual-slice CT (Reveal HD; CTI, Knoxville, Tennessee, USA). These PET images were acquired and reconstructed as described in a previous study [6] . In brief, PET scans were obtained with an acquisition time of 3-5 min/cradle position, with a 26.6% axial overlap at the borders of the field of view to avoid artifacts. PET images were reconstructed using orderedsubsets expectation maximization iterative algorithms with eight subsets, two iterations, and 128 × 128 pixels. The slice thickness was 2.4 mm and the pixel size within transverse slices was 5.2 mm, with 5 mm full-width at half-maximum three-dimensional Gaussian smoothing after reconstruction. We used the three-dimensional imaging mode with Fourier rebinning and analytic scatter correction. In a later group of 24 (21.8%) patients from April 2012 to November 2014, PET studies were acquired on a Siemens mCT scanner equipped with lutetium oxyorthosilicate scintillator crystals, time-offlight, and a 64-slice CT (Siemens Healthcare, Knoxville, Tennessee, USA). These PET images were reconstructed using time-of-flight ordered-subsets expectation maximization iterative reconstruction with 24 subsets and two iterations. The image matrix was 256 × 256, corresponding to a 3-mm in-plane pixel size with a plane thickness of 3 mm. Both PETs were calibrated to be accurate against our dose calibrator. In an additional 16 (14.5%) patients from February 2009 to December 2014, technically adequate whole-body 18 F-FDG PET/CT scans were obtained from external imaging centers.
All PET image analysis was carried out using the PET Edge tool of the MIM software (MIM Software Inc., Cleveland, Ohio, USA), which uses a gradient method, as described in previous studies ( Fig. 1 ) [4, 6] . The MTV, TLG, and SUV max of all the 18 F-FDG-avid tumors throughout the whole body were measured by a radiologist who had 10 years of experience in general radiology and was trained in 18 F-FDG PET/CT (X.Z.). A nuclear radiologist with more than 10 years of experience in 18 F-FDG PET checked every case that the general radiologist measured. The procedure was the same as described previously [6] . Both of the readers were blinded to patient survival status and survival time, but not blinded to the clinical information. They also made use of the PET/CT report and the diagnostic CT report.
Statistical analysis
Survival curves for OS were constructed using the Kaplan-Meier method and log-rank tests were carried out to evaluate OS differences among different patient groups.
The natural logarithmic transformation of the continuous variables (MTV WB , TLG WB , and SUV maxWB ) was used to achieve more normally distributed data. Univariate and multivariable Cox proportional-hazards models [19] were used to evaluate the association between OS and potential prognostic variables, including ln(MTV WB ), ln(TLG WB ), ln(SUV maxWB ), age, sex, lung cancer histological subtype, TNM stage, and lung cancer treatment type. All the variables in the Cox models fulfilled the proportional-hazards assumption, as tested using Schoenfeld residuals. To carry out multivariable Cox proportional-hazards analyses, a correlation coefficient matrix and the variance inflation factor were calculated to check for the problem of multicollinearity. The potential risk variables with either a P value less than 0.15 in the univariate Cox proportional-hazards models, or established clinical importance for OS, were included in a series of multivariable models. Gonen and Heller's Concordance Indices (GHCI), with a range from 0 to 1, provided a global assessment of the fitted Cox proportional hazard models and bootstrap methods were used to estimate the accuracies of GHCIs after model selection. All statistical tests were performed using STATA/SE software, version 14 (StataCorp LP, College Station, Texas, USA) and a two-tailed P value less than 0.05 was considered to indicate statistical significance.
Results

Patient characteristics
There were 203 consecutive NSCLC patients with a diagnosis of another type of primary cancer diagnosed/ treated in our hospital. Eighteen patients were excluded because the metachronous primary cancer(s) were confirmed more than 2 months following the 18 F-FDG PET/CT scan for the evaluation of NSCLC and another 75 patients were excluded because their metachronous primary cancers were diagnosed more than 5 years before their NSCLC diagnosis. Therefore, 110 patients (52 men and 58 women, mean age 68.6 years) were finally included in this study. One hundred and three patients presented with only one metachronous or synchronous primary cancer besides NSCLC and seven patients had two metachronous or synchronous primary cancers.
Among the 103 patients with one other primary cancer, 47 patients had one other synchronous cancer and 56 patients had one other metachronous cancer. Among the seven patients with two other primary cancers, one patient had two other synchronous cancers, four patients had two other metachronous cancers, and two patients had one other metachronous and one other synchronous cancer. In total, among the 110 patients in the current study, there were 117 other primary cancers, including 51 synchronous cancers and 66 metachronous cancers.
The characteristics of the patients are summarized in Table 1 . The origins of the other metachronous or synchronous primary cancers are shown in Table 2 . The median of the time interval between PET/CT scans and the diagnosis date of other synchronous cancer was one day before the PET/CT (range: 57 days before PET/CT to 60 days after PET/CT), whereas the median of the corresponding time interval for metachronous primary cancer was 1045 days (range: 69-1825 days before PET/ CT). Seventy-three patients died during follow-up. The median survival time was 2.4 years [95% confidence interval (CI): 0.9-4.3 years].
Kaplan-Meier analysis and the log-rank test There were statistically significant differences in OS between the groups separately dichotomized by the median values of MTV WB (P < 0.001), TLG WB (P < 0.001), and SUV maxWB (P < 0.001). Increased survival was observed in the patients with low values of these measures (Fig. 2) . There was also a statistically significant association of OS with TNM stage (P = 0.003) and treatment type (P < 0.001). No statistically significant association was observed between OS and quartiles of age (P = 0.175), sex (P = 0.371), or NSCLC histological subtype (P = 0.385).
Univariate Cox regression analysis
The univariate Cox regression analysis results are shown in Table 3 . There was a significant association of OS with ln(MTV WB ) (P < 0.001), ln(TLG WB ) (P < 0.001), ln(SUV maxWB ) (P < 0.001), TNM stage (stage III vs. stage I, P < 0.001; and stage IV vs. stage I, P < 0.01), and one of the lung cancer treatment types ('surgery' compared with no treatment, P < 0.001). The hazard ratio (HR) was 1.477 for ln(MTV WB ), 1.372 for ln(TLG WB ), and 1.983 for ln(SUV maxWB ). The HRs of TNM stage III and IV were 2.70 and 2.806 compared with stage I, respectively. The HR for 'surgery' compared with no cancer treatment was 0.228. Patients' age, sex, and tumor histology were not significantly associated with OS (all P > 0.05). On the basis of 500 bootstrap replicates, the GHCIs with 95% CIs for models containing ln (MTV WB ), ln(TLG WB ), and ln(SUV maxWB ) are shown in Table 3 . The GHCI values and their 95% CIs for ln (MTV WB ) and ln(TLG WB ) were similar and significantly greater than that of TNM stage (both P < 0.05). The GHCI of ln(SUV maxWB ) was not significantly different from that of the TNM stage (P = 0.183).
Multivariable Cox regression models
A correlation coefficient matrix showed that ln(TLG WB ) was strongly correlated with ln(MTV WB ) (r s = 0.97) and ln(SUV maxWB ) (r s = 0.84), and ln(SUV maxWB ) was moderately correlated with ln(MTV WB ) (r s = 0.72) [20] . The variance inflation factor of ln(MTV WB ) was 35.4 and that of ln(TLG WB ) was 51.3, suggesting that problems could be caused by multicollinearity between these variables, whereas that of ln(SUV maxWB ) was 5.1. Therefore, three final multivariable Cox regression models were established using ln(MTV WB ), ln(TLG WB ), or ln(SUV maxWB ) separately, and they showed that ln(MTV WB ), ln(TLG WB ), and ln(SUV maxWB ) were significantly associated with patient OS (all P < 0.01), even after adjusting for patient age, NSCLC clinical TNM stage, tumor histology, and treatment type. Patients who had undergone 'surgery' were associated with better OS compared with no cancer treatment [all P < 0.001 in the models containing ln(MTV WB ), ln(TLG WB ), and ln(SUV maxWB ), respectively]. TNM stages (stages II, III, and IV relative to stage I) were not significantly associated with OS in the multivariable Cox regression models (all P > 0.05). On the basis of 500 bootstrap replicates, the GHCI values and their 95% CIs for ln(MTV WB ), ln(TLG WB ), and ln(SUV maxWB ) were similar in the multivariable models (Table 4) .
Discussion
Quantitative PET measures such as TLG WB , MTV WB , and SUV maxWB have been shown to be significantly associated with patient OS in different types of malignant tumors including NSCLC [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . This study shows that baseline TLG WB , MTV WB , and SUV maxWB are associated independently with the OS of patients with an NSCLC and another metachronous or synchronous primary cancer, even after adjusting for patient age, TNM stage, tumor histology, and cancer therapy type. Patients with lower MTV WB , TLG WB , and SUV maxWB had better OS. The potential clinical implication is to use MTV WB , TLG WB , and/or SUV maxWB to further stratify patients into different risk groups as shown in Fig. 2 .
MTV WB and TLG WB measurements have not been used widely in clinical practice because manual segmentation of the tumor contour is time consuming. However, with advances in computer software, it has become less time consuming and practical for clinical use. Recently, we have shown that semiautomatic tumor segmentation and quantification can be used on primary tumors of NSCLC for this purpose and is much less time consuming than manual tumor segmentation and quantification [21] . In the current study, the tumor was segmented semiautomatically. The radiologists identified the center and long and short axes of each tumor in the body, and then the computer program automatically segmented the tumor. In rare cases, manual adjustment may be needed to segment the tumor. We also have shown that MTV measurement of the primary tumor in NSCLC varies less than SUV measurement between 1 and 2 h after an 18 F-FDG injection [22] . In addition, our group and others have also shown that MTV WB and TLG WB in NSCLC have low interobserver variability [3, 6, 7] .
The SUV max of the primary lung tumor has been the most commonly measured PET parameter when analyzing the prognostic capability of PET [23] . Although it remains a subject of debate as to whether SUV max provides additional prognostic information compared with the TNM stage [24, 25] , in this study, the whole-body tumor SUV max showed a statistically significant association with the patient OS in both univariate and multivariable Cox regression analyses, even after adjusting for other prognostic factors, including TNM stage.
As expected, the current study showed strong correlations of TLG WB with MTV WB , and SUV maxWB as TLG by definition is the product of MTV and SUV mean . Therefore, we believe that MTV WB and TLG WB are interchangeable in potential clinical applications of this study, but the correlation between MTV WB and SUV maxWB was moderate and they represent different PET tumor characteristics, whole-body metabolic tumor burden, and intensity of glucose metabolic activity, respectively.
The TNM stage is sometimes difficult to determine in NSCLC patients with a recent history of metachronous primary cancer or synchronous primary cancer; the tumors could be because of NSCLC or recurrence/ Except where indicated, data are represented as n (%). Sixty-one patients had surgery (15 with wedge resection, two with segmental resection, three with resection of more than one lobe, but less than the whole lung, 34 with lobectomy with mediastinal lymph node dissection, and seven resections greater than one lobe, but less than a full pneumonectomy).
Other treatments included chemotherapy and radiation therapy. Forty-eight patients received chemotherapy. Among these, 45 patients were treated with multiple chemotherapy agents including cis-platin or carboplatin and one or more other drugs (5-fluorouracil, ipilumimab, bevacizumab, etoposide, tarceva, cetuximab, gemcitabine, vinorelbine, navelbine, crizotinib, paclitaxel, taxotere, pemetrexed, or hydroxyurea). Two patients received chemotherapy with tarceva only and one with taxol only. In three patients, chemotherapy was recommended, but it is unknown whether it was performed. Thirty-seven patients received radiation therapy to the chest. For curative purposes, 21 patients were treated with three-dimensional conformal techniques with the conventional dose fractionation scheme and three were treated with Stereotactic Body Radiation Therapy techniques. One was with intensitymodulated radiotherapy, 11 patients received either palliative or incomplete therapy; treatment details for one patient were unknown. IQR, interquartile range; MTV WB , whole-body metabolic tumor volume; SUV maxWB , whole-body maximum standardized uptake value; TLG WB , whole-body total lesion glycolysis. Kaplan-Meier survival curves show significant differences in overall survival between groups dichotomized by the median value of MTV WB (a), TLG WB (b), and SUV maxWB (c). The log-rank tests yielded P < 0.001 for all. MTV WB , whole-body metabolic tumor volume; SUV maxWB , wholebody maximum standardised uptake value; TLG WB , whole-body total lesion glycolysis. In (a), MTV indicates MTV WB ; in (b), TLG indicates TLG WB ; and in (c) SUV max indicates SUV maxWB . There are some potential limitations to our study. First, this is a retrospective study and the results need to be further verified by other retrospective studies with a large sample size or by prospective observational studies. Second, we did not divide the patients into subgroups according to their other primary cancer type because of the relatively small sample size. The other primary cancers in this study cohort were heterogeneous in location, most commonly taking place in the lung or breast, followed by the head and neck, and, finally, the urinary system. Third, the performance status was not included in our survival analyses because not all patients included in this study had their performance status recorded in their medical records. However, the association of the performance status and OS has not been consistently reported in the literature [26] [27] [28] . Poor performance status can, in some cases, be because of high tumor burden [26] .
Conclusion
MTV WB , TLG WB , and SUV maxWB from the baseline 18 F-FDG PET/CT are individually associated with OS of patients with both NSCLC and metachronous or synchronous primary malignant tumors independent of age, treatment type, tumor histology, and TNM stage.
